HEOR

News

Vydura is first NICE-backed oral GPCR for acute migraine

Pfizer's Vydura has become the first drug in the oral GPCR receptor antagonist class to be recommended for routine NHS use as a treatment for acute migraine.

News

NICE changes its mind on Lilly's Mounjaro for diabetes

Around 180,000 people with type 2 diabetes in the UK could be in line for treatment with Eli Lilly's Mounjaro after the drug was recommended for NHS use by cost-effectiven

News

Keytruda backed for 'basket' of new cancers via NHS

The UK's cost-effectiveness agency NICE has recommended MSD's PD-1 inhibitor Keytruda for a series of cancers based on genetic abnormalities known as microsatellite instab

News

NICE won't budge on rejection of rare disease drug

The UK's cost-effectiveness agency NICE has delivered its final verdict on Clinuvel's Scenesse, a treatment for a rare skin disorder that causes extreme sensitivity to lig

News

New HTA body pledges to ‘cut the hype’ in digital health

US non-profit the Peterson Centre on Healthcare has launched a new institute, backed with $50 million in funding, that will take a close look at the clinical benefits and

News

BMS’ Sotyktu cleared for NHS use in psoriasis

Just a few weeks after its approval in the UK, Bristol-Myers Squibb’s new oral psoriasis therapy Sotyktu has been recommended for routine NHS in England and Wales.